On Wednesday, the drug maker Sun Pharmaceutical Industries said that it has got the US health regulator’s approval for its new drug application for treatment of acne medicine-Ximino TM extended- release capsules.

Sun Pharma said in a statement, The US Food and Drug Administration (USFDA) has approved the company’s supplemental New Drug Application (sNDA) for XiminoTM (Minocycline HCl) extended-release capsules in strengths of 45 mg, 90 mg and 135 mg.

“This approval further strengthens the company’s branded dermatology portfolio in the US. It expects XiminoTM extended-release capsules to be available for patients during the fourth quarter of 2015.”

Read other important stock market news